Merus to Present at the Leerink Partners 6th Annual Global Healthcare Conference
UTRECHT, The Netherlands, 2017-02-09 13:00 CET (GLOBE NEWSWIRE) --
Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will participate at the Leerink Partners 6thAnnual Global Healthcare Conference on Thursday, February 16, 2017 at 3:00 p.m. ET at the Lotte New York Palace Hotel.
A live webcast of the presentation will be available on the Investors page of the Company's website,http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, and Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
+1 973 361 1546
+1 646 368 8014
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Ved at skrive dig op her, vil du modtage pressemeddelelser på mail når de udsendes. Indtast din mail og følg instruktionerne. Det er ligeså let at melde sig fra igen.
Flere pressemeddelelser fra Nasdaq OMX
LogicBio Therapeutics, Inc.16.10.2017 15:01 | pressemeddelelse
LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin
CP Kelco16.10.2017 15:01 | pressemeddelelse
CP Kelco Appoints Didier Viala as New President
ASSIA Inc.16.10.2017 14:03 | pressemeddelelse
Telefonica Deploys ASSIA's GPON Expresse® Solution to optimize Fiber Broadband Performance
Concurrent Computer Corporation16.10.2017 14:03 | pressemeddelelse
Concurrent Enters Definitive Agreement to Sell Content Delivery & Storage Business to Vecima Networks for $29 Million
Fennec Pharmaceuticals16.10.2017 12:01 | pressemeddelelse
Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK(TM) (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting
Nexeo Solutions, Inc.16.10.2017 05:06 | pressemeddelelse
Nexeo Solutions to Distribute Vydyne® PA66 From Ascend
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum